The amalgamation is expected to bring in a lot of synergies in terms of operational efficiency and productivity for the combined entity
The pharma park will be built at an estimated cost of Rs 34.94 crore and will be spread over 50 acres at Chanho close to Ranchi
Proceeds raised from the duathlon will go towards cancer treatment of children identified by the hospital
This low-cost and highly reliable technology will help in increasing testing in rural and tribal areas
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastbone, da Vinci Xi's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Subscribe To Our Newsletter & Stay Updated
